Department of Surgery, University of California San Francisco School of Medicine, San Francisco, California.
Division of Geriatrics, University of California San Francisco School of Medicine, San Francisco, California; Northern California Institute for Research and Education, San Francisco, California.
J Surg Res. 2024 Jun;298:47-52. doi: 10.1016/j.jss.2024.02.017. Epub 2024 Mar 29.
Disparities in opioid prescribing by race/ethnicity have been described in many healthcare settings, with White patients being more likely to receive an opioid prescription than other races studied. As surgeons increase prescribing of nonopioid medications in response to the opioid epidemic, it is unknown whether postoperative prescribing disparities also exist for these medications, specifically gabapentinoids.
We conducted a retrospective cohort study using a 20% Medicare sample for 2013-2018. We included patients ≥66 years without prior gabapentinoid use who underwent one of 14 common surgical procedures. The primary outcome was the proportion of patients prescribed gabapentinoids at discharge among racial and ethnic groups. Secondary outcomes were days' supply of gabapentinoids, opioid prescribing at discharge, and oral morphine equivalent (OME) of opioid prescriptions. Trends over time were constructed by analyzing proportion of postoperative prescribing of gabapentinoids and opioids for each year. For trends by year by racial/ethnic groups, we ran a multivariable logistic regression with an interaction term of procedure year and racial/ethnic group.
Of the 494,922 patients in the cohort (54% female, 86% White, 5% Black, 5% Hispanic, mean age 73.7 years), 3.7% received a new gabapentinoid prescription. Gabapentinoid prescribing increased over time for all groups and did not differ significantly among groups (P = 0.13). Opioid prescribing also increased, with higher proportion of prescribing to White patients than to Black and Hispanic patients in every year except 2014.
We found no significant prescribing variation of gabapentinoids in the postoperative period between racial/ethnic groups. Importantly, we found that despite national attention to disparities in opioid prescribing, variation continues to persist in postoperative opioid prescribing, with a higher proportion of White patients being prescribed opioids, a difference that persisted over time.
在许多医疗保健环境中,种族/族裔之间的阿片类药物处方差异已经得到描述,与其他研究种族相比,白人患者更有可能获得阿片类药物处方。随着外科医生增加非阿片类药物的处方以应对阿片类药物流行,尚不清楚这些药物(特别是加巴喷丁类药物)是否也存在术后处方差异。
我们使用 2013 年至 2018 年的 Medicare 样本的 20%进行了回顾性队列研究。我们纳入了无既往加巴喷丁类药物使用史且年龄≥66 岁的患者,这些患者接受了 14 种常见手术之一。主要结局是在不同种族/族裔群体中,出院时开具加巴喷丁类药物的患者比例。次要结局是加巴喷丁类药物的供应天数、出院时开具的阿片类药物以及阿片类药物处方的口服吗啡当量(OME)。通过分析每年术后开具加巴喷丁类药物和阿片类药物的比例来构建随时间的趋势。对于按年份和种族/族裔群体的趋势,我们使用了一个多变量逻辑回归模型,其中包含一个手术年份和种族/族裔群体的交互项。
在队列中的 494922 名患者中(54%为女性,86%为白人,5%为黑人,5%为西班牙裔,平均年龄为 73.7 岁),有 3.7%的患者接受了新的加巴喷丁类药物处方。所有群体的加巴喷丁类药物处方数量随时间增加,并且在群体之间没有显著差异(P=0.13)。阿片类药物的处方也在增加,除了 2014 年之外,白人患者的处方比例始终高于黑人患者和西班牙裔患者。
我们没有发现术后期间种族/族裔群体之间加巴喷丁类药物处方存在显著差异。重要的是,我们发现,尽管国家关注阿片类药物处方差异,但术后阿片类药物处方的差异仍然存在,并且白人患者开具阿片类药物的比例更高,这种差异随着时间的推移而持续存在。